7月24日,江苏中慧元通生物科技股份有限公司(下称:“中慧元通”)二次递表,准备在港交所上市。这是继2025年1月23日递表未果后的再次努力。 此前,2023年6月,中慧元通曾寻求在上交所科创板上市,但2023年9月撤回申请,如今转道港股上市。 IPO日报,注意到,这家尚未盈利的疫苗公司,经历三轮融资总融到9.95亿元,但仍存在8.96亿元借款。此外,中慧元通还对刚上市不久的核心产品计提了重大...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.